Thoughts on Afami-cel’s Promising Clinical and Translational Data for SS and MRCLS; Adaptimmune’s Ph2 SPEARHEAD-1 Trial on Track to Meet Its Primary Endpoint by YE 2021
On Thursday, November 11, Adaptimmune reported (press release) updated clinical and translational data from afami-cel’s (MAGE-A4 SPEAR-T; formerly ADP-A2M4) Ph2 SPEARHEAD-1 trial for advanced synovial sarcoma (SS) and myxoid / round cell liposarcoma (MRCLS) at CTOS 2021. Below, Celltelligence provides insights on Adaptimmune’s CMC preparations ahead of afami-cel’s BLA filing, while discussing how afami-cel compares to GSK’s lete-cel (NY-ESO-1 TCR-T) in MRCLS.